Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $26.25

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $26.25.

TARA has been the topic of a number of research analyst reports. Oppenheimer boosted their price target on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Friday, July 17th. UBS Group reiterated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th.

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TARA. Geode Capital Management LLC boosted its holdings in Protara Therapeutics by 114.7% during the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock valued at $2,256,000 after acquiring an additional 397,822 shares during the period. JPMorgan Chase & Co. acquired a new position in Protara Therapeutics in the 2nd quarter valued at about $46,000. American Century Companies Inc. increased its stake in Protara Therapeutics by 69.8% during the second quarter. American Century Companies Inc. now owns 61,554 shares of the company’s stock worth $187,000 after purchasing an additional 25,305 shares during the period. New York State Common Retirement Fund purchased a new stake in Protara Therapeutics during the second quarter worth about $102,000. Finally, Invesco Ltd. purchased a new stake in Protara Therapeutics during the second quarter worth about $73,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Trading Up 2.5%

Shares of NASDAQ:TARA opened at $4.10 on Tuesday. The business has a 50-day moving average price of $4.07 and a 200 day moving average price of $5.09. The company has a market capitalization of $230.42 million, a price-to-earnings ratio of -3.06 and a beta of 1.50. Protara Therapeutics has a 12-month low of $2.97 and a 12-month high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. As a group, equities research analysts predict that Protara Therapeutics will post -1.44 earnings per share for the current fiscal year.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.